# Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

> **NCT04031846** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1184 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **DRUG:** Rotarix™
- **DRUG:** Infanrix™ hexa
- **DRUG:** V114
- **DRUG:** Prevenar 13™

## Key facts

- **NCT ID:** NCT04031846
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-04
- **Primary completion:** 2021-08-05
- **Final completion:** 2021-08-05
- **Target enrollment:** 1184 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031846, "Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04031846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*